Klein Peter Justin 4
4 · PhaseBio Pharmaceuticals Inc · Filed Oct 24, 2018
Insider Transaction Report
Form 4
Klein Peter Justin
Director
Transactions
- Conversion
Common Stock
2018-10-22+2,303→ 2,303 total - Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+103$12→ 2,306 total→ Common Stock (103 underlying) - Conversion
Series B Preferred Stock
2018-10-22−2,303→ 0 total→ Common Stock (2,303 underlying) - Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−103→ 0 totalExercise: $0.12→ Series B Preferred Stock (103 underlying) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−3$15→ 2,303 total→ Common Stock (3 underlying)
Footnotes (3)
- [F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- [F3]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.